A multicentre validation study of the diagnostic value of plasma neurofilament lightNicholas J. Ashton, Oskar Hansson, Markus Axelsson et al.|Nature Communications|2021Cited by 554
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Jan Lycke, Clas Malmeström et al.|Annals of Neurology|2010Cited by 347
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosisJan Lycke, Lars Rosengren, Oluf Andersen et al.|Journal of Neurology Neurosurgery & Psychiatry|1998Cited by 320
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MSClas Malmeström, Jan Lycke, Sara Haghighi et al.|Neurology|2003Cited by 318
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisTim Spelman, Jan Lycke, Melinda Magyari et al.|JAMA Neurology|2021Cited by 237